Risvutatug Rezetecan
瑞康立伏妥塔单抗
Report date: 2026/05/25 20:02:40
Base Information
Drug NameRisvutatug Rezetecan
Drug Alias Name
Classification +[4]
Mechanisms of Action
Targets
Therapy Area/Indications +[22]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[31]
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Hansoh Biomedical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesGlaxosmithkline PlcJiangsu Hansoh Pharmaceutical Group Co LtdShanghai Hansoh Biomedical Co Ltd +[6]
Inactive CompaniesN/A
Active Indications +[22]
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A